Allopregnanolone: State of the art

Progress in Neurobiology

Volumn 113, Issue , 2014, Pages 1-5

  Melcangi, Roberto Cosimo ^a   Panzica, Gian Carlo ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

Hippocampal development; Neuroactive steroid; Neurodegeneration; Neuroprotection; Pain; Pregnancy; Psychiatric disorders

Indexed keywords

3ALPHA HYDROXY 5ALPHA PREGNAN 20 ONE; CYCLODEXTRIN; MIGLUSTAT;

ALZHEIMER DISEASE; DRUG EFFICACY; MENTAL DISEASE; NERVOUS TISSUE; NEUROPROTECTION; NIEMANN PICK DISEASE; NONHUMAN; PARKINSON DISEASE; PREGNANCY; PRIORITY JOURNAL; REVIEW;

DHP; DIHYDROPROGESTERONE; HIPPOCAMPAL DEVELOPMENT; NEUROACTIVE STEROID; NEURODEGENERATION; NEUROPROTECTION; PAIN; PREGNANCY; PROG; PROGESTERONE; PSYCHIATRIC DISORDERS; TRANSLOCATOR PROTEIN OF 18KDA; TSPO;

ANIMALS; HUMANS; PREGNANOLONE;

EID: 84892882544     PISSN: 03010082     EISSN: 18735118     Source Type: Journal    
DOI: 10.1016/j.pneurobio.2013.09.005     Document Type: Review

References (111)

1. Adeosun S.O., Hou X., Jiao Y., Zheng B., Henry S., Hill R., He Z., Pani A., Kyle P., Ou X., Mosley T., Farley J.M., Stockmeier C., Paul I., Bigler S., Brinton R.D., Smeyne R., Wang J.M. Allopregnanolone reinstates tyrosine hydroxylase immunoreactive neurons and motor performance in an MPTP-lesioned mouse model of Parkinson's disease. PLoS One 2012, 7:e50040.
2. Ahmad I., Lope-Piedrafita S., Bi X., Hicks C., Yao Y., Yu C., Chaitkin E., Howison C.M., Weberg L., Trouard T.P., Erickson R.P. Allopregnanolone treatment, both as a single injection or repetitively, delays demyelination and enhances survival of Niemann-Pick C mice. J. Neurosci. Res. 2005, 82:811-821.
3. Azcoitia I., Leonelli E., Magnaghi V., Veiga S., Garcia-Segura L.M., Melcangi R.C. Progesterone and its derivatives dihydroprogesterone and tetrahydroprogesterone reduce myelin fiber morphological abnormalities and myelin fiber loss in the sciatic nerve of aged rats. Neurobiol. Aging 2003, 24:853-860.
4. Backstrom T., Bixo M., Johansson M., Nyberg S., Ossewaarde L., Ragagnin G., Savic I., Stromberg J., Timby E., van Broekhoven F., van Wingen G. Allopregnanolone and mood disorders. Prog. Neurobiol. 2013, 10.1016/j.pneurobio.2013.07.005.
5. Backstrom T., Wahlstrom G., Wahlstrom K., Zhu D., Wang M.D. Isoallopregnanolone; an antagonist to the anaesthetic effect of allopregnanolone in male rats. Eur. J. Pharmacol. 2005, 512:15-21.
6. Banks J.A., Freeman M.E. Inhibition of the daily LH release mechanism by progesterone acting at the hypothalamus. Biol. Reprod. 1980, 22:217-222.
7. Barraclough C.A., Camp P., Weiland N., Akabori A. Stimulatory versus inhibitory effects of progesterone on estrogen-induced phasic LH and prolactin secretion correlated with estrogen nuclear and progestin cytosol receptor concentrations in brain and pituitary gland. Neuroendocrinology 1986, 42:6-14.
8. Barron A.M., Garcia-Segura L.M., Caruso D., Jayaraman A., Lee J.W., Melcangi R.C., Pike C.J. Ligand for translocator protein reverses pathology in a mouse model of Alzheimer's disease. J. Neurosci. 2013, 33:8891-8897.
9. Beckley E.H., Fretwell A.M., Tanchuck M.A., Gililland K.R., Crabbe J.C., Finn D.A. Decreased anticonvulsant efficacy of allopregnanolone during ethanol withdrawal in female withdrawal seizure-prone vs withdrawal seizure-resistant mice. Neuropharmacology 2008, 54:365-374.
10. Belelli D., Bolger M.B., Gee K.W. Anticonvulsant profile of the progesterone metabolite 5 alpha-pregnan-3 alpha-ol-20-one. Eur. J. Pharmacol. 1989, 166:325-329.
11. Belelli D., Lambert J.J. Neurosteroids: endogenous regulators of the GABA(A) receptor. Nat. Rev. Neurosci. 2005, 6:565-575.
12. Biggio G., Cristina Mostallino M., Follesa P., Concas A., Sanna E. GABA(A) receptor function and gene expression during pregnancy and postpartum. Int. Rev. Neurobiol. 2009, 85:73-94.
13. Bitran D., Hilvers R.J., Kellogg C.K. Anxiolytic effects of 3 alpha-hydroxy-5 alpha[beta]-pregnan-20-one: endogenous metabolites of progesterone that are active at the GABAA receptor. Brain Res. 1991, 561:157-161.
14. Bourque M., Dluzen D.E., Di Paolo T. Neuroprotective actions of sex steroids in Parkinson's disease. Front. Neuroendocrinol. 2009, 30:142-157.
15. Brann D.W., Mahesh V.B. Regulation of gonadotropin secretion by steroid hormones. Front. Neuroendocrinol. 1991, 12:165-207.
16. Brinton R.D. Neurosteroids as regenerative agents in the brain: therapeutic implications. Nat. Rev. Endocrinol. 2013, 9:241-250.
17. Brunton P.J., Russell J.A., Hirst J.J. Allopregnanolone in the brain: protecting pregnancy and birth outcomes. Prog. Neurobiol. 2013.
18. Callier S., Morissette M., Grandbois M., Pelaprat D., Di Paolo T. Neuroprotective properties of 17beta-estradiol, progesterone, and raloxifene in MPTP C57Bl/6 mice. Synapse 2001, 41:131-138.
19. Caruso D., Barron A.M., Brown M.A., Abbiati F., Carrero P., Pike C.J., Garcia-Segura L.M., Melcangi R.C. Age-related changes in neuroactive steroid levels in 3xTg-AD mice. Neurobiol. Aging 2013, 34:1080-1089.
20. Caruso D., D'Intino G., Giatti S., Maschi O., Pesaresi M., Calabrese D., Garcia-Segura L.M., Calza L., Melcangi R.C. Sex-dimorphic changes in neuroactive steroid levels after chronic experimental autoimmune encephalomyelitis. J. Neurochem. 2010, 114:921-932.
21. Caruso D., Pesaresi M., Maschi O., Giatti S., Garcia-Segura L.M., Melcangi R.C. Effects of short- and long-term gonadectomy on neuroactive steroid levels in the central and peripheral nervous system of male and female rats. J. Neuroendocrinol. 2010, 22:1137-1147.
22. Caruso D., Scurati S., Maschi O., De Angelis L., Roglio I., Giatti S., Garcia-Segura L.M., Melcangi R.C. Evaluation of neuroactive steroid levels by liquid chromatography-tandem mass spectrometry in central and peripheral nervous system: effect of diabetes. Neurochem. Int. 2008, 52:560-568.
23. Caruso D., Scurati S., Roglio I., Nobbio L., Schenone A., Melcangi R.C. Neuroactive steroid levels in a transgenic rat model of CMT1A neuropathy. J. Mol. Neurosci. 2008, 34:249-253.
24. Cermenati G., Brioschi E., Abbiati F., Melcangi R.C., Caruso D., Mitro N. Liver X receptors, nervous system, and lipid metabolism. J. Endocrinol. Invest. 2013, 36:435-443.
25. Cermenati G., Giatti S., Cavaletti G., Bianchi R., Maschi O., Pesaresi M., Abbiati F., Volonterio A., Saez E., Caruso D., Melcangi R.C., Mitro N. Activation of the liver X receptor increases neuroactive steroid levels and protects from diabetes-induced peripheral neuropathy. J. Neurosci. 2010, 30:11896-11901.
26. Chan J.R., Phillips L.J., Glaser M. Glucocorticoids and progestins signal the initiation and enhance the rate of myelin formation. Proc. Natl. Acad. Sci. USA 1998, 95:10459-10464.
27. Chan J.R., Rodriguez-Waitkus P.M., Ng B.K., Liang P., Glaser M. Progesterone synthesized by Schwann cells during myelin formation regulates neuronal gene expression. Mol. Biol. Cell 2000, 11:2283-2295.
28. Chen S., Wang J.M., Irwin R.W., Yao J., Liu L., Brinton R.D. Allopregnanolone promotes regeneration and reduces beta-amyloid burden in a preclinical model of Alzheimer's disease. PLoS One 2011, 6:e24293.
29. Ciriza I., Azcoitia I., Garcia-Segura L.M. Reduced progesterone metabolites protect rat hippocampal neurones from kainic acid excitotoxicity in vivo. J. Neuroendocrinol. 2004, 16:58-63.
30. Ciriza I., Carrero P., Frye C.A., Garcia-Segura L.M. Reduced metabolites mediate neuroprotective effects of progesterone in the adult rat hippocampus, the synthetic progestin medroxyprogesterone acetate (Provera) is not neuroprotective. J. Neurobiol. 2006, 66:916-928.
31. Corpechot C., Robel P., Axelson M., Sjovall J., Baulieu E.E. Characterization and measurement of dehydroepiandrosterone sulfate in rat brain. Proc. Natl. Acad. Sci. USA 1981, 78:4704-4707.
32. Czlonkowska A.I., Krzascik P., Sienkiewicz-Jarosz H., Siemiatkowski M., Szyndler J., Bidzinski A., Plaznik A. The effects of neurosteroids on picrotoxin-, bicuculline- and NMDA-induced seizures, and a hypnotic effect of ethanol. Pharmacol. Biochem. Behav. 2000, 67:345-353.
33. Darbra S., Modol L., Llido A., Casas C., Vallee M., Pallares M. Neonatal allopregnanolone levels alteration: effects on behavior and role of the hippocampus. Prog. Neurobiol. 2013, 10.1016/j.pneurobio.2013.07.007.
34. Daugherty D.J., Selvaraj V., Chechneva O.V., Liu X.B., Pleasure D.E., Deng W. A TSPO ligand is protective in a mouse model of multiple sclerosis. EMBO Mol. Med. 2013, 5:891-903.
35. Djebaili M., Hoffman S.W., Stein D.G. Allopregnanolone and progesterone decrease cell death and cognitive deficits after a contusion of the rat pre-frontal cortex. Neuroscience 2004, 123:349-359.
36. Eser D., Baghai T.C., Schule C., Nothdurfter C., Rupprecht R. Neuroactive steroids as endogenous modulators of anxiety. Curr. Pharm. Des. 2008, 14:3525-3533.
37. Ficher M., Steinberger E. In vitro progesterone metabolism by rat testicular tissue at different stages of development. Acta Endocrinol. (Copenh.) 1971, 68:285-292.
38. Frye C.A., Scalise T.J. Anti-seizure effects of progesterone and 3alpha, 5alpha-THP in kainic acid and perforant pathway models of epilepsy. Psychoneuroendocrinology 2000, 25:407-420.
39. Garay L., Deniselle M.C., Lima A., Roig P., De Nicola A.F. Effects of progesterone in the spinal cord of a mouse model of multiple sclerosis. J. Steroid Biochem. Mol. Biol. 2007, 107:228-237.
40. Garay L., Deniselle M.C., Meyer M., Costa J.J., Lima A., Roig P., Denicola A.F. Protective effects of progesterone administration on axonal pathology in mice with experimental autoimmune encephalomyelitis. Brain Res. 2009, 1283:177-185.
41. Garcia-Segura L.M., Luquin S., Parducz A., Naftolin F. Gonadal hormone regulation of glial fibrillary acidic protein immunoreactivity and glial ultrastructure in the rat neuroendocrine hypothalamus. Glia 1994, 10:59-69.
42. Ghoumari A.M., Baulieu E.E., Schumacher M. Progesterone increases oligodendroglial cell proliferation in rat cerebellar slice cultures. Neuroscience 2005, 135:47-58.
43. Ghoumari A.M., Ibanez C., El-Etr M., Leclerc P., Eychenne B., O'Malley B.W., Baulieu E.E., Schumacher M. Progesterone and its metabolites increase myelin basic protein expression in organotypic slice cultures of rat cerebellum. J. Neurochem. 2003, 86:848-859.
44. Giachino C., Galbiati M., Fasolo A., Peretto P., Melcangi R. Neurogenesis in the subependymal layer of the adult rat: a role for neuroactive derivatives of progesterone. Ann. N. Y. Acad. Sci. 2003, 1007:335-339.
45. Giatti S., Caruso D., Boraso M., Abbiati F., Ballarini E., Calabrese D., Pesaresi M., Rigolio R., Santos-Galindo M., Viviani B., Cavaletti G., Garcia-Segura L.M., Melcangi R.C. Neuroprotective effects of progesterone in chronic experimental autoimmune encephalomyelitis. J. Neuroendocrinol. 2012, 24:851-861.
46. Giatti S., D'Intino G., Maschi O., Pesaresi M., Garcia-Segura L.M., Calza L., Caruso D., Melcangi R.C. Acute experimental autoimmune encephalomyelitis induces sex dimorphic changes in neuroactive steroid levels. Neurochem. Int. 2010, 56:118-127.
47. Giatti S., Pesaresi M., Cavaletti G., Bianchi R., Carozzi V., Lombardi R., Maschi O., Lauria G., Garcia-Segura L.M., Caruso D., Melcangi R.C. Neuroprotective effects of a ligand of translocator protein-18kDa (Ro5-4864) in experimental diabetic neuropathy. Neuroscience 2009, 164:520-529.
48. Girard C., Liu S., Cadepond F., Adams D., Lacroix C., Verleye M., Gillardin J.M., Baulieu E.E., Schumacher M., Schweizer-Groyer G. Etifoxine improves peripheral nerve regeneration and functional recovery. Proc. Natl. Acad. Sci. USA 2008, 105:20505-20510.
49. Girard P., Pansart Y., Gillardin J.M. Preventive and curative effects of etifoxine in a rat model of brain oedema. Clin. Exp. Pharmacol. Physiol. 2009, 36:655-661.
50. Girdler S.S., Klatzkin R. Neurosteroids in the context of stress: implications for depressive disorders. Pharmacol. Ther. 2007, 116:125-139.
51. Griffin L.D., Gong W., Verot L., Mellon S.H. Niemann-Pick type C disease involves disrupted neurosteroidogenesis and responds to allopregnanolone. Nat. Med. 2004, 10:704-711.
52. Grobin A.C., Morrow A.L. 3Alpha-hydroxy-5alpha-pregnan-20-one levels and GABA(A) receptor-mediated 36Cl(-) flux across development in rat cerebral cortex. Dev. Brain Res. 2001, 131:31-39.
53. He J., Evans C.O., Hoffman S.W., Oyesiku N.M., Stein D.G. Progesterone and allopregnanolone reduce inflammatory cytokines after traumatic brain injury. Exp. Neurol. 2004, 189:404-412.
54. Hovakimyan M., Maass F., Petersen J., Holzmann C., Witt M., Lukas J., Frech M.J., Hubner R., Rolfs A., Wree A. Combined therapy with cyclodextrin/allopregnanolone and miglustat improves motor but not cognitive functions in Niemann-Pick type C1 mice. Neuroscience 2013, 252:201-211.
55. Ibanez C., Shields S.A., El-Etr M., Leonelli E., Magnaghi V., Li W.W., Sim F.J., Baulieu E.E., Melcangi R.C., Schumacher M., Franklin R.J. Steroids and the reversal of age-associated changes in myelination and remyelination. Prog. Neurobiol. 2003, 71:49-56.
56. Ishrat T., Sayeed I., Atif F., Hua F., Stein D.G.C.P. Progesterone and allopregnanolone attenuate blood-brain barrier dysfunction following permanent focal ischemia by regulating the expression of matrix metalloproteinases. Exp. Neurol. 2010, 226:183-190.
57. Irwin R.W., Brinton R.D. Allopregnanolone as regenerative therapeutic for Alzheimer's disease: translational development and clinical promise. Prog. Neurobiol. 2013, 10.1016/j.pneurobio.2013.08.004.
58. Kawano T., Soga T., Chi H., Eguchi S., Yamazaki F., Kumagai N., Yokoyama M. Role of the neurosteroid allopregnanolone in the hyperalgesic behavior induced by painful nerve injury in rats. J. Anesth. 2011, 25:942-945.
59. Labombarda F., Ghoumari A.M., Liere P., De Nicola A.F., Schumacher M., Guennoun R. Neuroprotection by steroids after neurotrauma in organotypic spinal cord cultures: a key role for progesterone receptors and steroidal modulators of GABAA receptors. Neuropharmacology 2013, 71:46-55.
60. Labombarda F., Pianos A., Liere P., Eychenne B., Gonzalez S., Cambourg A., De Nicola A.F., Schumacher M., Guennoun R. Injury elicited increase in spinal cord neurosteroid content analyzed by gas chromatography mass spectrometry. Endocrinology 2006, 147:1847-1859.
61. Lambert J.J., Belelli D., Peden D.R., Vardy A.W., Peters J.A. Neurosteroid modulation of GABAA receptors. Prog. Neurobiol. 2003, 71:67-80.
62. Leonelli E., Bianchi R., Cavaletti G., Caruso D., Crippa D., Garcia-Segura L.M., Lauria G., Magnaghi V., Roglio I., Melcangi R.C. Progesterone and its derivatives are neuroprotective agents in experimental diabetic neuropathy: a multimodal analysis. Neuroscience 2007, 144:1293-1304.
63. Leonelli E., Yague J.G., Ballabio M., Azcoitia I., Magnaghi V., Schumacher M., Garcia-Segura L.M., Melcangi R.C. Ro5-4864, a synthetic ligand of peripheral benzodiazepine receptor, reduces aging-associated myelin degeneration in the sciatic nerve of male rats. Mech. Ageing Dev. 2005, 126:1159-1163.
64. Liao G., Cheung S., Galeano J., Ji A.X., Qin Q., Bi X. Allopregnanolone treatment delays cholesterol accumulation and reduces autophagic/lysosomal dysfunction and inflammation in Npc1-/- mouse brain. Brain Res. 2009, 1270:140-151.
65. Lonsdale D., Burnham W.M. The anticonvulsant effects of allopregnanolone against amygdala-kindled seizures in female rats. Neurosci. Lett. 2007, 411:147-151.
66. Lonsdale D., Nylen K., McIntyre Burnham W. The anticonvulsant effects of progesterone and its metabolites on amygdala-kindled seizures in male rats. Brain Res. 2006, 1101:110-116.
67. Luquin S., Naftolin F., Garcia-Segura L.M. Natural fluctuation and gonadal hormone regulation of astrocyte immunoreactivity in dentate gyrus. J. Neurobiol. 1993, 24:913-924.
68. Meffre D., Pianos A., Liere P., Eychenne B., Cambourg A., Schumacher M., Stein D.G., Guennoun R. Steroid profiling in brain and plasma of male and pseudopregnant female rats after traumatic brain injury: analysis by gas chromatography/mass spectrometry. Endocrinology 2007, 148:2505-2517.
69. Melcangi R.C., Azcoitia I., Ballabio M., Cavarretta I., Gonzalez L.C., Leonelli E., Magnaghi V., Veiga S., Garcia-Segura L.M. Neuroactive steroids influence peripheral myelination: a promising opportunity for preventing or treating age-dependent dysfunctions of peripheral nerves. Prog. Neurobiol. 2003, 71:57-66.
70. Melcangi R.C., Caruso D., Levandis G., Abbiati F., Armentero M.T., Blandini F. Modifications of neuroactive steroid levels in an experimental model of nigrostriatal degeneration: potential relevance to the pathophysiology of Parkinson's disease. J. Mol. Neurosci. 2012, 46:177-183.
71. Melcangi R.C., Garcia-Segura L.M. Sex-specific therapeutic strategies based on neuroactive steroids: in search for innovative tools for neuroprotection. Horm. Behav. 2010, 57:2-11.
72. Melcangi R.C., Garcia-Segura L.M., Mensah-Nyagan A.G. Neuroactive steroids: state of the art and new perspectives. Cell Mol. Life Sci. 2008, 65:777-797.
73. Melcangi R.C., Giatti S., Calabrese D., Pesaresi M., Cermenati G., Mitro N., Viviani B., Garcia-Segura L.M., Caruso D. Levels and actions of progesterone and its metabolites in the nervous system during physiological and pathological conditions. Prog. Neurobiol. 2013, 10.1016/j.pneurobio.2013.07.006.
74. Melcangi R.C., Giatti S., Pesaresi M., Calabrese D., Mitro N., Caruso D., Garcia-Segura L.M. Role of neuroactive steroids in the peripheral nervous system. Front. Endocrinol. (Lausanne) 2011, 2:104.
75. Melcangi R.C., Panzica G., Garcia-Segura L.M. Neuroactive steroids: focus on human brain. Neuroscience 2011, 191:1-5.
76. Meyer L., Patte-Mensah C., Taleb O., Mensah-Nyagan A.G. Cellular and functional evidence for a protective action of neurosteroids against vincristine chemotherapy-induced painful neuropathy. Cell Mol. Life Sci. 2010, 67:3017-3034.
77. Meyer L., Patte-Mensah C., Taleb O., Mensah-Nyagan A.G. Allopregnanolone prevents and suppresses oxaliplatin-evoked painful neuropathy: multi-parametric assessment and direct evidence. Pain 2011, 152:170-181.
78. Micevych P., Sinchak K. Synthesis and function of hypothalamic neuroprogesterone in reproduction. Endocrinology 2008, 149:2739-2742.
79. Micevych P., Sinchak K. The neurosteroid progesterone underlies estrogen positive feedback of the LH surge. Front. Endocrinol. (Lausanne) 2011, 2:90.
80. Mitro N., Cermenati G., Giatti S., Abbiati F., Pesaresi M., Calabrese D., Garcia-Segura L.M., Caruso D., Melcangi R.C. LXR and TSPO as new therapeutic targets to increase the levels of neuroactive steroids in the central nervous system of diabetic animals. Neurochem. Int. 2012, 60:616-621.
81. Mòdol L., Casas C., Llidó A., Navarro X., Pallarès M., Darbra S. Alteration of allopregnanolone levels affects alpha4 and delta GABAA receptor subunit expression and adult behavioural hippocampal response to neurosteroids. FENS Forum Abstr. 2012, A-471-0184-01765.
82. Morali G., Montes P., Gonzalez-Burgos I., Velazquez-Zamora D.A., Cervantes M. Cytoarchitectural characteristics of hippocampal CA1 pyramidal neurons of rats, four months after global cerebral ischemia and progesterone treatment. Restor. Neurol. Neurosci. 2012, 30:1-8.
83. Noorbakhsh F., Ellestad K.K., Maingat F., Warren K.G., Han M.H., Steinman L., Baker G.B., Power C. Impaired neurosteroid synthesis in multiple sclerosis. Brain 2011, 134:2703-2721.
84. Nothdurfter C., Rammes G., Baghai T.C., Schule C., Schumacher M., Papadopoulos V., Rupprecht R. Translocator protein (18kDa) as a target for novel anxiolytics with a favourable side-effect profile. J. Neuroendocrinol. 2012, 24:82-92.
85. Nothdurfter C., Rupprecht R., Rammes G. Recent developments in potential anxiolytic agents targeting GABAA/BzR complex or the translocator protein (18kDa) (TSPO). Curr. Top. Med. Chem. 2012, 12:360-370.
86. Paris J.J., Brunton P.J., Russell J.A., Walf A.A., Frye C.A. Inhibition of 5 alpha-reductase activity in late pregnancy decrease gestational length and fecundity and imapairs object memory and central progestrogen milieu of juvenile rat offspring. J. Neuroendocrinol. 2011, 23:1079-1090.
87. Papadopoulos V., Lecanu L. Translocator protein (18kDa) TSPO: an emerging therapeutic target in neurotrauma. Exp. Neurol. 2009, 219:53-57.
88. Patte-Mensah C., Meyer L., Taleb O., Mensah-Nyagan A.G. Potential role of allopregnanolone for a safe and effective therapy of neuropathic pain. Prog. Neurobiol. 2013, 10.1016/j.pneurobio.2013.07.004.
89. Pelletier G. Steroidogenic enzymes in the brain: morphological aspects. Prog. Brain Res. 2010, 181:193-207.
90. Pesaresi M., Maschi O., Giatti S., Garcia-Segura L.M., Caruso D., Melcangi R.C. Sex differences in neuroactive steroid levels in the nervous system of diabetic and non-diabetic rats. Horm. Behav. 2010, 57:46-55.
91. Pinna G. In a mouse model relevant for post-traumatic stress disorder, selective brain steroidogenic stimulants (SBSS) improve behavioral deficits by normalizing allopregnanolone biosynthesis. Behav. Pharmacol. 2010, 21:438-450.
92. Roglio I., Bianchi R., Gotti S., Scurati S., Giatti S., Pesaresi M., Caruso D., Panzica G.C., Melcangi R.C. Neuroprotective effects of dihydroprogesterone and progesterone in an experimental model of nerve crush injury. Neuroscience 2008, 155:673-685.
93. Sayeed I., Guo Q., Hoffman S.W., Stein D.G. Allopregnanolone, a progesterone metabolite, is more effective than progesterone in reducing cortical infarct volume after transient middle cerebral artery occlusion. Ann. Emerg. Med. 2006, 47:381-389.
94. Sayeed I., Parvez S., Wali B., Siemen D., Stein D.G. Direct inhibition of the mitochondrial permeability transition pore: a possible mechanism for better neuroprotective effects of allopregnanolone over progesterone. Brain Res. 2009, 1263:165-173.
95. Schüle C., Nothdurfter C., Rupprecht R. The role of allopregnanolone in depression and anxiety. Prog. Neurobiol. 2013, 111. 10.1016/j.pneurobio.2013.09.003.
96. Schumacher M., Hussain R., Gago N., Oudinet J.P., Mattern C., Ghoumari A.M. Progesterone synthesis in the nervous system: implications for myelination and myelin repair. Front. Neurosci. 2012, 6:10.
97. Schumacher M., Weill-Engerer S., Liere P., Robert F., Franklin R.J., Garcia-Segura L.M., Lambert J.J., Mayo W., Melcangi R.C., Parducz A., Suter U., Carelli C., Baulieu E.E., Akwa Y. Steroid hormones and neurosteroids in normal and pathological aging of the nervous system. Prog. Neurobiol. 2003, 71:3-29.
98. Schumacher M., Mattern C., Ghoumari A., Oudinet J.-P., Liere P., Labombarda F., Sitruk-Ware R., De Nicola A.F., Guennoun R. Revisiting the roles of progesterone and allopregnanolone in the nervous system: resurgence of the progesterone receptors. Prog. Neurobiol. 2013, 111. 10.1016/j.pneurobio.2013.09.004.
99. Singh S., Hota D., Prakash A., Khanduja K.L., Arora S.K., Chakrabarti A. Allopregnanolone, the active metabolite of progesterone protects against neuronal damage in picrotoxin-induced seizure model in mice. Pharmacol. Biochem. Behav. 2010, 94:416-422.
100. Skinner D.C., Evans N.P., Delaleu B., Goodman R.L., Bouchard P., Caraty A. The negative feedback actions of progesterone on gonadotropin-releasing hormone secretion are transduced by the classical progesterone receptor. Proc. Natl. Acad. Sci. USA 1998, 95:10978-10983.
101. Stein D.G. Progesterone in the treatment of acute traumatic brain injury: a clinical perspective and update. Neuroscience 2011, 191:101-106.
102. Tsutsui K. Neurosteroid biosynthesis and action during cerebellar development. Cerebellum 2012, 11:414-415.
103. Tsutsui K., Ukena K., Sakamoto H., Okuyama S., Haraguchi S. Biosynthesis, mode of action, and functional significance of neurosteroids in the Purkinje cell. Front. Endocrinol. (Lausanne) 2011, 2:61.
104. Turkmen S., Backstrom T., Wahlstrom G., Andreen L., Johansson I.M. Tolerance to allopregnanolone with focus on the GABA-A receptor. Br. J. Pharmacol. 2011, 162:311-327.
105. VanLandingham J.W., Cekic M., Cutler S., Hoffman S.W., Stein D.G.C.P. Neurosteroids reduce inflammation after TBI through CD55 induction. Neurosci. Lett. 2007, 425:94-98.
106. VanLandingham J.W., Cutler S.M., Virmani S., Hoffman S.W., Covey D.F., Krishnan K., Hammes S.R., Jamnongjit M., Stein D.G. The enantiomer of progesterone acts as a molecular neuroprotectant after traumatic brain injury. Neuropharmacology 2006, 51:1078-1085.
107. Veiga S., Azcoitia I., Garcia-Segura L.M. Ro5-4864, a peripheral benzodiazepine receptor ligand, reduces reactive gliosis and protects hippocampal hilar neurons from kainic acid excitotoxicity. J. Neurosci. Res. 2005, 80:129-137.
108. Wang J.M., Liu L., Irwin R.W., Chen S., Brinton R.D. Regenerative potential of allopregnanolone. Brain. Res. Rev. 2008, 57:398-409.
109. Wang J.M., Singh C., Liu L., Irwin R.W., Chen S., Chung E.J., Thompson R.F., Brinton R.D. Allopregnanolone reverses neurogenic and cognitive deficits in mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA 2010, 107:6498-6503.
110. Wang M., He Y., Eisenman L.N., Fields C., Zeng C.M., Mathews J., Benz A., Fu T., Zorumski E., Steinbach J.H., Covey D.F., Zorumski C.F., Mennerick S. 3Beta-hydroxypregnane steroids are pregnanolone sulfate-like GABA(A) receptor antagonists. J. Neurosci. 2002, 22:3366-3375.
111. Wirth M.M. Beyond the HPA axis: progesterone-derived neuroactive steroids in human stress and emotion. Front. Endocrinol. (Lausanne) 2011, 2:19.